Monthly PubMed Review

Monthly PubMed Review of the Most relevant research on Lung Cancer

December 2019

BASIC AND APPLIED SCIENCE, PRE-CLINICAL STUDIES

microRNAs Tune Oxidative Stress in Cancer Therapeutic Tolerance and Resistance. Zhang WC1. Int J Mol Sci. 2019 Dec 3;20(23). pii: E6094. doi: 10.3390/ijms20236094.

Influence of miR-199a on rats with non-small cell lung cancer via regulating the HIF-1α/VEGF signaling pathway. Wang LM1, Zhang LL, Wang LW, Zhu L, Ma XX. Eur Rev Med Pharmacol Sci. 2019 Dec;23(23):10363-10369. doi: 10.26355/eurrev_201912_19675.

Robot-assisted bronchoscopy for pulmonary lesion diagnosis: results from the initial multicenter experience. Chaddha U1, Kovacs SP2, Manley C3, Hogarth DK4, Cumbo-Nacheli G5, Bhavani SV4, Kumar R3, Shende M6, Egan JP 3rd5, Murgu S4. BMC Pulm Med. 2019 Dec 11;19(1):243. doi: 10.1186/s12890-019-1010-8.

SCREENING, DIAGNOSIS, BIOMARKER TESTING, AND STAGING

Validation of the eighth edition clinical T categorization system for clinical stage IA resected lung adenocarcinomas: Prognostic implications of the ground-glass opacity component. Kim H1, Goo JM2, Kim YT3, Park CM4. J Thorac Oncol. 2019 Dec 23. pii: S1556-0864(19)33851-1. doi: 10.1016/j.jtho.2019.12.110. [Epub ahead of print]

Association of invitation to lung cancer screening and tobacco use outcomes in a VA demonstration project. Fu SS1,2, Melzer AC1,2,3, Fabbrini AE3, Rice KL3, Clothier B1, Nelson DB1,2, Doro EA1, Partin MR1,2. Prev Med Rep. 2019 Nov 17;16:101023. doi: 10.1016/j.pmedr.2019.101023. eCollection 2019 Dec.

18F-FDG PET/CT in restaging and evaluation of response to therapy in lung cancer: state of art. Castello A1, Rossi S2, Lopci E1. Curr Radiopharm. 2019 Dec 30. doi: 10.2174/1874471013666191230144821. [Epub ahead of print]

TMPRSS4: A Novel Tumor Prognostic Indicator for the Stratification of Stage IA Tumors and a Liquid Biopsy Biomarker for NSCLC Patients. Villalba M1,2,3, Exposito F1,2,3, Pajares MJ1,2,3, et al. J Clin Med. 2019 Dec 3;8(12). pii: E2134. doi: 10.3390/jcm8122134.

Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges. Rijavec E1, Coco S2, Genova C2, Rossi G2,3, Longo L2, Grossi F1. Cancers (Basel). 2019 Dec 19;12(1). pii: E17. doi: 10.3390/cancers12010017.

Multidisciplinary Team Based Management of Incidentally Detected Lung Nodules. Verdial FC1, Madtes DK2, Cheng GS2, Pipavath S3, Kim R4, Hubbard JJ5, Zadworny M1, Wood DE1, Farjah F6. Chest. 2019 Dec 17. pii: S0012-3692(19)34401-0. doi: 10.1016/j.chest.2019.11.032. [Epub ahead of print]

Integrated, Multidisciplinary Management of Pulmonary Nodules Can Streamline Care and Improve Adherence to Recommendations. Roberts TJ1,2, Lennes IT1,3,2,4, Hawari S1, et al. Oncologist. 2019 Dec 26. doi: 10.1634/theoncologist.2019-0519. [Epub ahead of print]

Evaluating Lung Cancer Screening Across Diverse Healthcare Systems: A Process Model from the Lung PROSPR Consortium. Rendle KA1, Burnett-Hartman AN2, Neslund-Dudas C3, et al. Cancer Prev Res (Phila). 2019 Dec 23. pii: canprevres.0378.2019. doi: 10.1158/1940-6207.CAPR-19-0378. [Epub ahead of print]

The Role of c-Met as a Biomarker and Player in Innate and Acquired Resistance in Non-Small-Cell Lung Cancer: Two New Mutations Warrant Further Studies. Van Der Steen N1,2,3, Zwaenepoel K1,2, Mazzaschi G4, et al. Molecules. 2019 Dec 4;24(24). pii: E4443. doi: 10.3390/molecules24244443.

Effectiveness of Intraoperative Pulmonary Wedge Resection of Tumor Site Before Lobectomy for Early Lung Adenocarcinoma. Yasukawa M1, Sawabata N2, Kawaguchi T2, Taniguchi S2. Anticancer Res. 2019 Dec;39(12):6829-6834. doi: 10.21873/anticanres.13899.

NSCLC SURGERY

Survival disparities following surgery among patients with different histological types of non-small cell lung cancer. Grosu HB1, Manzanera A2, Shivakumar S3, Sun S4, Noguras Gonzalez G5, Ost DE6. Lung Cancer. 2019 Dec 17;140:55-58. doi: 10.1016/j.lungcan.2019.12.007. [Epub ahead of print]

Comparison of Double Sleeve Lobectomy by Uniportal Video-Assisted Thoracic Surgery (VATS) and Thoracotomy for NSCLC Treatment. Wu L1, Wang H2, Cai H1, Fan J1, Jiang G1, He Y3, Jiang L1. Cancer Manag Res. 2019 Dec 2;11:10167-10174. doi: 10.2147/CMAR.S226459. eCollection 2019.

Digital pathology for intraoperative frozen section diagnosis of thoracic specimens: an evaluation of a system using remote sampling and whole slide imaging diagnosis.Griffin J1, Kitsanta P2, Perunovic B2, Suvarna SK2, Bury J2. J Clin Pathol. 2019 Dec 5. pii: jclinpath-2019-206236. doi: 10.1136/jclinpath-2019-206236. [Epub ahead of print]

Predicting Severe Postoperative Complication in Patients with Lung Cancer and Interstitial Pneumonia. Ohsawa M1, Tsutani Y1, Fujiwara M1, Mimae T1, Miyata Y1, Okada M2. Ann Thorac Surg. 2019 Dec 27. pii: S0003-4975(19)31925-3. doi: 10.1016/j.athoracsur.2019.11.012. [Epub ahead of print]

Impact on Health-Related Quality of Life of Video-Assisted Thoracoscopic Surgery for Lung Cancer. Avery KNL1, Blazeby JM1,2, Chalmers KA1, et al. Ann Surg Oncol. 2019 Dec 1. doi: 10.1245/s10434-019-08090-4. [Epub ahead of print]

NSCLC – SYSTEMIC THERAPIES (CHEMOTHERAPY, TARGETED THERAPY, AND IMMUNOTHERAPY)

Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer. Kichenadasse G1,2, Miners JO1, Mangoni AA1, Rowland A1, Hopkins AM1, Sorich MJ1. JAMA Oncol. 2019 Dec 26. doi: 10.1001/jamaoncol.2019.5241. [Epub ahead of print]

Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer. Bradley JD1, Hu C2,3, Komaki RR4, et al. J Clin Oncol. 2019 Dec 16:JCO1901162. doi: 10.1200/JCO.19.01162. [Epub ahead of print]

Comparison between 18F-FDG-PET- and CT-based criteria in non-small cell lung cancer (NSCLC) patients treated with Nivolumab. Rossi G1, Bauckneht M2, Genova C1, et al. J Nucl Med. 2019 Dec 5. pii: jnumed.119.233056. doi: 10.2967/jnumed.119.233056. [Epub ahead of print]

Anlotinib Combined with S-1 in the Third-Line Treatment of Stage IV Non-Small Cell Lung Cancer: Study Protocol for Phase II Clinical Trial. Yang X1,2, Xiang M1, Geng L1,2, Wen Y1,2, Du X1. Asian Pac J Cancer Prev. 2019 Dec 1;20(12):3849-3853. doi: 10.31557/APJCP.2019.20.12.3849.

Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. Lim ZF1,2,3, Ma PC4. J Hematol Oncol. 2019 Dec 9;12(1):134. doi: 10.1186/s13045-019-0818-2.

Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer. Leighl NB1, Karaseva N2, Nakagawa K3, Cho BC4, Gray JE5, Hovey T6, Walding A7, Rydén A8, Novello S9. Eur J Cancer. 2019 Dec 12;125:49-57. doi: 10.1016/j.ejca.2019.11.006. [Epub ahead of print]

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Drilon A1, Siena S2, Dziadziuszko R3, et al. Lancet Oncol. 2019 Dec 11. pii: S1470-2045(19)30690-4. doi: 10.1016/S1470-2045(19)30690-4. [Epub ahead of print]

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Doebele RC1, Drilon A2, Paz-Ares L3, et al. Lancet Oncol. 2019 Dec 11. pii: S1470-2045(19)30691-6. doi: 10.1016/S1470-2045(19)30691-6. [Epub ahead of print]

Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations. Reck M1, Shankar G2, Lee A2, Coleman S2, McCleland M2, Papadimitrakopoulou VA3, Socinski MA4, Sandler A2. Expert Rev Respir Med. 2019 Dec 12:1-12. doi: 10.1080/17476348.2020.1701439. [Epub ahead of print]

Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). Cho JH1, Lim SH2, An HJ3, et al. J Clin Oncol. 2019 Dec 11:JCO1900931. doi: 10.1200/JCO.19.00931. [Epub ahead of print]

Osimertinib for patients with leptomeningeal metastases associated with epidermal growth factor receptor T790M positive advanced NSCLC: the AURA LM analysis. Ahn MJ1, Chiu CH2, Cheng Y3, et al. J Thorac Oncol. 2019 Dec 27. pii: S1556-0864(19)33854-7. doi: 10.1016/j.jtho.2019.12.113. [Epub ahead of print]

Phase II study of bevacizumab, cisplatin, and pemetrexed in advanced non-squamous non-small cell lung cancer (NS-NSCLC) with EGFR wild-type. Murakami S1, Saito H1, Kondo T1, Oshita F2, Yamada K1. J Exp Ther Oncol. 2019 Dec;13(2):131-138.

Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L). Seto T1, Azuma K2, Yamanaka T3, et al. J Clin Oncol. 2019 Dec 27:JCO1901494. doi: 10.1200/JCO.19.01494. [Epub ahead of print]

Predictive factors for progression-free survival in non-small cell lung cancer patients receiving nivolumab based on performance status. Adachi Y1, Tamiya A1, Taniguchi Y1, Enomoto T1, Azuma K1, Kouno S1, Inagaki Y1, Saijo N1, Okishio K2, Atagi S2. Cancer Med. 2019 Dec 27. doi: 10.1002/cam4.2807. [Epub ahead of print]

NSCLC - RADIOTHERAPY

High dose radiation therapy based on normal tissue constraints with concurrent chemotherapy achieves promising survival of patients with unresectable stage III non-small cell lung cancer. Zhao Q1, Liu M2, Wang Z1, et al. Radiother Oncol. 2019 Dec 20;145:7-12. doi: 10.1016/j.radonc.2019.11.024. [Epub ahead of print]

Assessment of precision irradiation in early non-small cell lung cancer and interstitial lung disease (ASPIRE-ILD): study protocol for a phase II trial. Palma DA1, Chen H2, Bahig H3, et al. BMC Cancer. 2019 Dec 11;19(1):1206. doi: 10.1186/s12885-019-6392-8.

Radiomics of 18F-FDG PET/CT images predicts clinical benefit of advanced NSCLC patients to checkpoint blockade immunotherapy. Mu W1, Tunali I1, Gray JE2, Qi J1, Schabath MB2,3, Gillies RJ4. Eur J Nucl Med Mol Imaging. 2019 Dec 5. doi: 10.1007/s00259-019-04625-9. [Epub ahead of print]

“Dose of the day” based on cone beam computed tomography and deformable image registration for lung cancer radiotherapy. Yuan Z1,2, Rong Y1, Benedict SH1, Daly ME1, Qiu J3, Yamamoto T1. J Appl Clin Med Phys. 2019 Dec 9. doi: 10.1002/acm2.12793. [Epub ahead of print]

SMALL CELL LUNG CANCER - SCLC

Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic Small-Cell Lung Cancer: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. Chung HC1, Piha-Paul SA2, Lopez-Martin J3, Schellens JHM4, et al. J Thorac Oncol. 2019 Dec 20. pii: S1556-0864(19)33850-X. doi: 10.1016/j.jtho.2019.12.109. [Epub ahead of print]

Clinical outcome for small cell lung cancer patients with bone metastases at the time of diagnosis. Gong L1, Xu L1, Yuan Z1, Wang Z1, Zhao L1, Wang P1. J Bone Oncol. 2019 Nov 2;19:100265. doi: 10.1016/j.jbo.2019.100265. eCollection 2019 Dec.

The prognostic role of PET/CT in small-cell lung cancer. Budak E1, Yanarateş A2, Akgün A3. Rev Esp Med Nucl Imagen Mol. 2019 Dec 18. pii: S2253-654X(19)30129-5. doi: 10.1016/j.remn.2019.09.003. [Epub ahead of print]

The prognostic role of circulating CD8+ T cell proliferation in patients with untreated extensive stage small cell lung cancer. An N1, Wang H2, Jia W3, Jing W3, Liu C3, Zhu H4, Yu J5,6. J Transl Med. 2019 Dec 3;17(1):402. doi: 10.1186/s12967-019-02160-7.

Recent progress in mapping the emerging landscape of the small-cell lung cancer genome. Kim KB1, Dunn CT2, Park KS3. Exp Mol Med. 2019 Dec 12;51(12):157. doi: 10.1038/s12276-019-0349-5.

Different distant metastasis patterns based on tumor size could be found in extensive-stage small cell lung cancer patients: a large, population-based SEER study. Li J#1, Liu F#1, Yu H2, Zhao C3, Li Z4, Wang H5. PeerJ. 2019 Dec 3;7:e8163. doi: 10.7717/peerj.8163. eCollection 2019.

The role of postoperative thoracic radiotherapy and prophylactic cranial irradiation in early stage small cell lung cancer: Patient selection among ESTRO experts. Putora PM1, De Ruysscher D2, Glatzer M3, et al. Radiother Oncol. 2019 Dec 27;145:45-48. doi: 10.1016/j.radonc.2019.11.022. [Epub ahead of print]

PALLIATIVE AND SUPPORTIVE CARE

Deterioration in Muscle Mass and Physical Function Differs According to Weight Loss History in Cancer Cachexia. Stene GB1,2,3, Balstad TR2,3, Leer ASM1,2, et al. Cancers (Basel). 2019 Dec 3;11(12). pii: E1925. doi: 10.3390/cancers11121925.

Decision-making factors for best supportive care alone and prognostic factors after best supportive care in non-small cell lung cancer patients. Kitazawa H1, Takeda Y2, Naka G2, Sugiyama H2. Sci Rep. 2019 Dec 27;9(1):19872. doi: 10.1038/s41598-019-56431-w.

COMPLEMENTARY & ALTERNATIVE THERAPY

Auricular acupressure for cancer-related fatigue during lung cancer chemotherapy: a randomised trial. Lin L#1,2, Zhang Y#3, Qian HY1, Xu JL1, Xie CY2, Dong B2, Tian L4,2. BMJ Support Palliat Care. 2019 Dec 13. pii: bmjspcare-2019-001937. doi: 10.1136/bmjspcare-2019-001937. [Epub ahead of print]

MISCELLANEOUS WORKS

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. Ettinger DS1, Wood DE2, Aggarwal C3, et al. J Natl Compr Canc Netw. 2019 Dec;17(12):1464-1472. doi: 10.6004/jnccn.2019.0059.

From clinical specimens to human cancer preclinical models-a journey the NCI-cell line database-25 years later. Mulshine JL1, Ujhazy P2, Antman M3, et al. J Cell Biochem. 2019 Dec 5. doi: 10.1002/jcb.29564. [Epub ahead of print]

A way forward for cancer prevention therapy: personalized risk assessment. Zhang Z1, Bien J2, Mori M3,4, Jindal S5, Bergan R1. Oncotarget. 2019 Dec 3;10(64):6898-6912. doi: 10.18632/oncotarget.27365. eCollection 2019 Dec 3.

E-cigarette flavored pods induce inflammation, epithelial barrier dysfunction, and DNA damage in lung epithelial cells and monocytes. Muthumalage T1, Lamb T1, Friedman MR2, Rahman I3. Sci Rep. 2019 Dec 13;9(1):19035. doi: 10.1038/s41598-019-51643-6.

Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline. Schneider BJ1, Ismaila N2, Aerts J3, et al. J Clin Oncol. 2019 Dec 12:JCO1902748. doi: 10.1200/JCO.19.02748. [Epub ahead of print]

Survival, Chemotherapy Treatments, and Health Care Utilization Among Patients with Advanced Small Cell Lung Cancer: An Observational Study. He J1, Shao C2, Hui SL3, Zhang Z3,4, Baker J3, Dexter PR3, Kachroo S2, Jin F2. Adv Ther. 2019 Dec 11. doi: 10.1007/s12325-019-01161-8. [Epub ahead of print]

Whole Exome Sequencing of Highly Aggregated Lung Cancer Families Reveals Linked Loci for Increased Cancer Risk on Chromosomes 12q, 7p and 4q. Musolf AM1, Moiz BA1, Sun H1,3 et al. Cancer Epidemiol Biomarkers Prev. 2019 Dec 11. pii: cebp.0887.2019. doi: 10.1158/1055-9965.EPI-19-0887. [Epub ahead of print]

Racial Disparities in Resection of Early Stage Non-Small Cell Lung Cancer: Variability Among Surgeons. Ezer N1,2, Mhango G2, Bagiella E3, Goodman E2, Flores R4, Wisnivesky JP2,5. Med Care. 2019 Dec 30. doi: 10.1097/MLR.0000000000001280. [Epub ahead of print]

Archives